Excerpts

This assumption was strongly supported by clinical data from large-scale gene expression data sets (TCGA database), which revealed a highly significant correlation between FOXO3 and ITGA5 expression in ERα+, but not in ERα−, BC patients ( Figure 3 i).

Further, significant portions of TRMs expand during murine PDAC progression and exhibit a pro-fibrotic transcriptional profile and a strong trend towards poor survival when mapped to human PDAC datasets.

Although a decreasing trend has been observed globally, its prevalence remains high in several parts of the world such as Asia, Eastern Europe, and South America [ 1 ].

Interestingly, these genera showed a trend to increase from healthy controls to OPMDs with their highest level seen in OSCC [ 29 ].

For example, in patients receiving nivolumab within the CheckMate 040 trial, higher CD3+ or CD8+ T cells infiltrate in pre-treatment tumour samples showed a trend toward improved OS, and increased CD3+ correlated with objective response [ 15 ].

In addition, hypoxanthine presented an elevated trend in the HCT group, whereas xanthine declined drastically, which was consistent with the prior metabolomics analysis of paired HCC tissues [ 12 ].

It is worth noting that the low-risk group with high levels of immune infiltration in our study showed a trend consistent with previous studies.

In the IGAS clusters, each immune cell type expressed extremely significant differences ( Figure 7 A,B).

These studies, while recording a positive trend of a lower incidence of second tumors after the introduction of a smaller radiation volume, such as IFRT, suffered from a lack of specific volumetric and dosimetric data regarding the RT treatment actually delivered and the volume of the organs at risk (OAR) irradiated.

When analyzed in a multivariable analysis, there was a trend toward significance for radiation field volume, only for all-cause mortality, probably due to the small number of events within each treatment period.

ΔpBK-ITIH5-induced tumors showed a highly significant reduction in relative blood volume compared with ΔpBK-mock tumors ( Figure 1 G).

The p -value for deviation from linearity of the dose–response association was nearly significant (0.071) only for the main analysis.

The PT/FA cluster showed a slight trend to separate FA from PT, but overlap currently remains high and without a clear distinction between PT histologically diagnosed as benign, borderline, or malignant ( Figure 1 D). 3.5.

There was a higher expression of TNF and a clearly significant higher expression of IL6 and MKI67 after treatment with 1 mg/mL H-HA/L-HA compared to the control in both irradiation groups (7.13- and 5.76-fold after 2 Gy irradiation, 4.40- and 5.50-fold after 5 Gy irradiation) ( Figure 5 b,c). 3.4.

Tam 2.0 tool overrepresentation analysis [ 33 , 34 ] was also performed with all nominally significant DE miRNAs as inputs and the settings of all curated miRNAs as background, limited to a miRNA set size of two, including up- and down-regulated miRNA sets. 2.5.

According to our data, the majority of the tested PET parameters with different thresholds including SUVmax, MTV2.5, MTV3, TLG2.5, TLG3, and TLG30% discriminated DFS with statistical significance and with marginal significance for MTV30% and TLG40%.

The differences in DFS rates between cut-off levels were statistically significant in SUVmax, MTV2.5, MTV3, TLG2.5, TLG3, and TLG30%, and at least marginally significant in rest of the PET parameters ( Table 2 ).

Interestingly, we observed a numerical trend that patients with a homozygous 5/5 genotype were more likely to be PR-negative.

We thus explored the role of significant factors in the above Cox and logistic regression multivariate analyses (radiotherapy and surgery against hypothalamic involvement) and found a highly significant effect of hypothalamic involvement (OR 6.1, 95% CI 1.7–21.7, p 0.005), as well as radiation (OR 16.2, 95%CI 1.7–158.6, p 0.017) and surgical intervention (OR 4.8 95% CI 1.3–17.2, p 0.015), to influence the onset of APD, with no factor prevailing on the others. 2.6.

CD44v6-Positive CR-CSphCs Are Refractory toward BRAF Inhibition While treatment with an inhibitor of BRAF (vemurafenib) reduced the clonogenic activity and delayed in vitro growth of BRAF -mutant CR-CSphCs, the clonogenicity of RAS/BRAF -wt (wt) and KRAS -mutant cells showed a trend towards an increase, without altering the proliferation rate ( Figure 1 A,B and Table 1 ).

However, the CF patients’ life expectancy has been on an increasing trend, largely due to new medications and therapy options [ 60 ].

0 h), with a decreasing trend visible also on normal mature B-cells which however did not reach statistical significance ( Figure 2 B).

Furthermore, patients treated with a combination of PD1 inhibitors and chemotherapy showed a trend to a better response than those treated only with chemotherapy, underlining the potential synergy among the two treatments [ 16 ].

Patients with stage T2 tumors who received a PTVmax ≥ 125 Gy (BED 10 ) showed a trend toward improved LC, yet there were no significant differences in comparison with those who received a PTVmax < 125 Gy (BED 10 ).

[ 20 ] looked at the mean annual hours of bright sunlight in Australia, finding a significant trend of ORs in CM risk with more hours among native-born Australians (so longer exposure) and a reduction among migrants; however, the adjustment for sun sensitivity was unclear.